Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
ApexOnco Front Page
Recent articles
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
And that could affect the drug's third-line accelerated approval.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
But PFS data are lacking, and there are questions about first and second-line plans.
